PFE (Pfizer) 6-1 Month Momentum % : -10.76% (As of Jul. 10, 2025)

View and export this data going back to 1951. Start your Free Trial

What is Pfizer 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2025-07-10), Pfizer's 6-1 Month Momentum % is -10.76%.

The industry rank for Pfizer's 6-1 Month Momentum % or its related term are showing as below:

PFE's 6-1 Month Momentum % is ranked worse than
69.4% of 1049 companies
in the Drug Manufacturers industry
Industry Median: -0.81 vs PFE: -10.76

Competitive Comparison of Pfizer's 6-1 Month Momentum %

For the Drug Manufacturers - General subindustry, Pfizer's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pfizer's 6-1 Month Momentum % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pfizer's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Pfizer's 6-1 Month Momentum % falls into.

Save Embed

;

Save Embed

;

Pfizer (NYSE:PFE) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %

( Price 1-month ago

Price 6-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pfizer (NYSE:PFE) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Pfizer 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Pfizer's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pfizer Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pfizer Inc (NYSE:PFE) » Definitions » 6-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

PFE:Peru PFE:Mexico PFE_KZ:Kazakhstan 1PFE:Italy PFEd:UK 0Q1N:UK PFEB:Germany PFE:Germany PFE:Germany PFE:Germany PFE:Germany PFE:Chile PFE:Canada PFIZ34:Brazil PFE:Bulgaria PFE:Austria PFE:Argentina

Address

66 Hudson Boulevard East, New York, NY, USA, 10001-2192

Website

https://www.pfizer.com

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Executives

Jennifer B. Damico	officer: SVP & Controller	C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Ronald E Blaylock	director
Scott Gottlieb	director	MOLECULAR INSIGHT PHARMACEUTICALS, 160 SECOND STREET, CAMBRIDGE MA 02142
Christoffel Boshoff	officer: Executive Vice President	66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192
Payal Sahni	officer: Executive Vice President	ATTN: PFIZER CORP. SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017
Carapezzi William R Jr	officer: Executive Vice President	600 MOUNTAIN AVENUE, MURRAY HILL NJ 07921
Douglas M Lankler	officer: Senior Vice President	PFIZER INC. ATTN: CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Mikael Dolsten	officer: Senior Vice President	5 GIRALDA FARMS, MADISON NJ 07940
David M Denton	officer: Chief Financial Officer & EVP	1000 LOWE'S BOULEVARD, MOORESVILLE NC 28117
William Pao	officer: Executive Vice President	C/O CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Michael Mcdermott	officer: Executive Vice President	C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, 235 EAST 42ND STREET NY 10017
Rady A Johnson	officer: Executive Vice President	PFIZER INC. ATTN CORP. SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Alexander R Mackenzie	officer: Executive Vice President	C/O PFIZER CORP. SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Sally Susman	officer: Senior Vice President	767 FIFTH AVE, EOTIC LAWDER CORP, NEW YORK NY 10153
Angela Hwang	officer: Group President	235 EAST 42ND STREET, ATTN: CORPORATE SECRETARY, NEW YORK NY 10017